【摘要】 目的探讨瑞替普酶(r-PA)和尿激酶溶栓治疗急性心肌梗死(AMI)的临床疗效和安全性。方法 98例符合溶栓治疗的急性心肌梗死患者中,瑞替普酶溶栓治疗组47例,尿激酶溶栓治疗组51例,比较2组的临床再通率,4周内出血发生率及死亡率。结果瑞替普酶组临床再通率高于尿激酶组(85.1%VS66.7%),差异有统计学意义(P=0.034);瑞替普酶组出血发生率低于尿激酶组(6.4%VS11.8%),但差异无统计学意义(P=0.357);瑞替普酶组死亡率低于尿激酶组(4.3%VS5.9%),但2组间差异无统计学意义(P=0.715)。结论瑞替普酶溶栓治疗急性心肌梗死的临床疗效和安全性优于尿激酶。更多还原

【Abstract】 Objctive To investigate the curative effect and safety of Reteplase and Urokinase in acute myocardial infarction(AMI).Methods 98 patients with AMI were divided into Reteplase group(47cases) and Urokinase group(51cases).The recanalization rate,bleeding rate and death rate in 4 weeks of the two groups were analyzed.Results Reteplase group had a higher recanalization rate than Urokinase group(85.1%VS66.7%),there was statistical significances between the two groups(P=0.034).The bleeding rate and death rate of 4 weeks were lower in Reteplase group(6.4%VS11.8% and 4.3%VS5.9%),but there was no statistical significances between the two groups(P=0.357 and P=0.715).Conclusions The curative effect and safety of Reteplase in the treatment of AMI are superior to Urokinase.更多还原